PubMed Journal Database | Neurology(R) neuroimmunology & neuroinflammation RSS

02:57 EST 28th February 2020 | BioPortfolio

The US National Library of Medicine and National Institutes of Health manage which comprises of more than 29 million records, papers, reports for biomedical literature, including MEDLINE, life science and medical journals, articles, reviews, reports and  books.

BioPortfolio aims to cross reference relevant information on published papers, clinical trials and news associated with selected topics - speciality.

For example view all recent relevant publications on Epigenetics and associated publications and clincial trials.

Showing PubMed Articles 1–25 of 29 from Neurology(R) neuroimmunology & neuroinflammation

Clinical features of seronegative, but CSF antibody-positive, anti-NMDA receptor encephalitis.

To determine the frequency of anti-NMDA receptor encephalitis without detectable serum NMDAR antibodies and to compare the clinical features of these patients with those with NMDAR antibodies in serum and CSF.

Identification of circulating MOG-specific B cells in patients with MOG antibodies.

Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE).

Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors.

To report the induction of anti-Ma2 antibody-associated paraneoplastic neurologic syndrome (Ma2-PNS) in 6 patients after treatment with immune checkpoint inhibitors (ICIs). We also analyzed (1) patient clinical features compared with a cohort of 44 patients who developed Ma2-PNS without receiving ICI treatment and (2) the frequency of neuronal antibody detection before and after ICI implementation.

HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease.

We investigated the associations with HLA and microtubule-associated protein tau () H1 haplotype in anti-IgLON5 disease, a recently identified disorder characterized by gait instability, brainstem dysfunction, and a prominent sleep disorder in association with IgLON5 antibodies and pathologic findings of a novel neuronal-specific tauopathy.

Steroid-sparing agents for the treatment of inflammation in complicated neurocysticercosis.

Does CSF pleocytosis have a predictive value for disease course in MS?

MS is a demyelinating CNS disorder with a spectrum of clinical patterns regarding course and prognosis. Although several prognostic factors are considered in the initial evaluation of patients, biological markers defining the disease course and guiding treatments are currently lacking. It is unknown whether patients with CSF pleocytosis differ in regard to symptoms, disease course, and prognosis from those without. The aim of this study was to evaluate whether CSF pleocytosis during the initial presentation...

Tumefactive demyelination in a patient with relapsing-remitting MS on ocrelizumab.

Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD.

To develop a resource of systematically collected, longitudinal clinical data and biospecimens for assisting in the investigation into neuromyelitis optica spectrum disorder (NMOSD) epidemiology, pathogenesis, and treatment.

Gray matter microglial activation in relapsing vs progressive MS: A F-18PBR06-PET study.

To determine the value of [F-18]PBR06-PET for assessment of microglial activation in the cerebral gray matter in patients with MS.

Systemic inflammatory response syndrome and long-term outcome after intracerebral hemorrhage.

To investigate whether the systemic inflammatory response syndrome (SIRS) without infection as surrogate of a systemic immune response is associated with poor long-term functional outcome in patients with spontaneous intracerebral hemorrhage (ICH).

Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.

This phase I study investigated pharmacokinetic (PK) and pharmacodynamic (PD) profiles of natalizumab in pediatric patients with relapsing-remitting MS (RRMS).

Novel clinical features of glycine receptor antibody syndrome: A series of 17 cases.

To describe novel clinical features of GlyRα1-IgG-positive patients.

Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study.

To investigate the long-term safety and efficacy of weekly subcutaneous IgPro20 (Hizentra, CSL Behring) in chronic inflammatory demyelinating polyneuropathy (CIDP).

Randomized, controlled crossover study of IVIg for demyelinating polyneuropathy and diabetes.

To determine whether IV immunoglobulin (IVIg) is more effective than placebo at reducing disability in patients with diabetes and demyelinating polyneuropathy features.

Hepatitis E virus infections in patients with MS on oral disease-modifying treatment.

To test whether patients with MS on disease-modifying treatments (DMTs) are at a higher risk of acute or chronic hepatitis E virus (HEV) infections or extrahepatic manifestations, we monitored approximately 1,100 persons with MS (pwMS) during 3 years for HEV infection.

Lesion activity and chronic demyelination are the major determinants of brain atrophy in MS.

To evaluate the combined effect of lesion activity and pathologic processes occurring in both chronically demyelinated lesions and normal-appearing white matter (NAWM) on brain atrophy in MS.

Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS.

We explored the incremental value of adding multiple disease activity biomarkers in CSF and serum for distinguishing MRI-based benign from aggressive MS in early disease course.

Chronic inflammatory demyelinating polyneuropathy associated with contactin-1 antibodies in a child.

Peripherally derived macrophages as major phagocytes in MOG encephalomyelitis.

Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE).

To evaluate the safety and efficacy of cholecalciferol in patients with relapsing-remitting MS (RRMS).

Relationship between retinal inner nuclear layer, age, and disease activity in progressive MS.

To investigate whether inner nuclear layer (INL) thickness as assessed with optical coherence tomography differs between patients with progressive MS (P-MS) according to age and disease activity.

Neurofilament light chain levels in MS: At the doorstep of clinical application.

Anti-pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy.

To identify and characterize patients with autoantibodies against different neurofascin (NF) isoforms.

Cervical spinal cord atrophy: An early marker of progressive MS onset.

To assess whether cervical spinal cord atrophy heralds the onset of progressive MS.

Quick Search